TWI722661B - 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 - Google Patents

用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 Download PDF

Info

Publication number
TWI722661B
TWI722661B TW108141496A TW108141496A TWI722661B TW I722661 B TWI722661 B TW I722661B TW 108141496 A TW108141496 A TW 108141496A TW 108141496 A TW108141496 A TW 108141496A TW I722661 B TWI722661 B TW I722661B
Authority
TW
Taiwan
Prior art keywords
cancer
peptide
cell
cells
tumor
Prior art date
Application number
TW108141496A
Other languages
English (en)
Chinese (zh)
Other versions
TW202024126A (zh
Inventor
安德列 馬爾
湯尼 文史恩克
奧利佛 史古兒
金斯 弗里切
哈皮特 辛格
Original Assignee
德商英麥提克生物技術股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商英麥提克生物技術股份有限公司 filed Critical 德商英麥提克生物技術股份有限公司
Publication of TW202024126A publication Critical patent/TW202024126A/zh
Application granted granted Critical
Publication of TWI722661B publication Critical patent/TWI722661B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
TW108141496A 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 TWI722661B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562211276P 2015-08-28 2015-08-28
GBGB1515321.6A GB201515321D0 (en) 2015-08-28 2015-08-28 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB1515321.6 2015-08-28
US62/211,276 2015-08-28

Publications (2)

Publication Number Publication Date
TW202024126A TW202024126A (zh) 2020-07-01
TWI722661B true TWI722661B (zh) 2021-03-21

Family

ID=54326487

Family Applications (15)

Application Number Title Priority Date Filing Date
TW108141496A TWI722661B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141494A TWI722659B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW105127400A TW201708246A (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW109122012A TWI782290B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141499A TWI722664B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141489A TWI722655B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141497A TWI722662B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141491A TWI722657B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141487A TWI722653B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141490A TWI722656B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141498A TWI722663B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW107128393A TWI699377B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141492A TWI722658B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141495A TWI722660B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141488A TWI722654B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架

Family Applications After (14)

Application Number Title Priority Date Filing Date
TW108141494A TWI722659B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW105127400A TW201708246A (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW109122012A TWI782290B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141499A TWI722664B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141489A TWI722655B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141497A TWI722662B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141491A TWI722657B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141487A TWI722653B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141490A TWI722656B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141498A TWI722663B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW107128393A TWI699377B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141492A TWI722658B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141495A TWI722660B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
TW108141488A TWI722654B (zh) 2015-08-28 2016-08-26 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架

Country Status (18)

Country Link
US (7) US10525114B2 (https=)
EP (2) EP3341014A1 (https=)
JP (2) JP6970974B2 (https=)
KR (3) KR20180038550A (https=)
CN (1) CN107921111B (https=)
AU (3) AU2016313684B2 (https=)
BR (1) BR112018003460A2 (https=)
CA (2) CA2996963A1 (https=)
CR (6) CR20180174A (https=)
EA (2) EA201891874A3 (https=)
GB (1) GB201515321D0 (https=)
MA (7) MA43461B1 (https=)
MX (1) MX2018002480A (https=)
PE (2) PE20181164A1 (https=)
SG (3) SG10202001830PA (https=)
TW (15) TWI722661B (https=)
UA (1) UA124577C2 (https=)
WO (1) WO2017036936A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
CN108250286B (zh) * 2016-12-28 2021-06-08 香雪生命科学技术（广东）有限公司 源自于pasd1的肿瘤抗原短肽
TW201841937A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
MY197772A (en) 2017-04-10 2023-07-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
KR20200071740A (ko) * 2017-09-28 2020-06-19 임팩트-바이오 리미티드. 저해성 키메라 항원 수용체 (icar)를 제조하기 위한 보편적 플랫폼
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CN109467596B (zh) * 2018-11-12 2021-11-09 湖北省农业科学院畜牧兽医研究所 转录因子sp1在调控猪rtl1基因表达中的应用
CN109738929B (zh) * 2018-12-03 2022-10-21 中国辐射防护研究院 一种基于居民食物最大消费量的剂量估算方法及系统
TWI858016B (zh) * 2019-02-18 2024-10-11 日商肽夢想股份有限公司 血球凝集素結合肽
JPWO2020230792A1 (https=) * 2019-05-13 2020-11-19
CN110123453B (zh) * 2019-05-31 2021-07-23 东北大学 一种基于无标记增强现实的手术导航系统
US20230158132A1 (en) * 2020-04-14 2023-05-25 Universite De Montreal Novel tumor-specific antigens for acute lymphoblastic leukemia (all) and uses thereof
CN111910000B (zh) * 2020-07-02 2022-07-01 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及系统
CN117425665A (zh) * 2021-04-19 2024-01-19 得克萨斯州大学系统董事会 包含mhc i类肽的方法和组合物
CN117957012A (zh) * 2021-07-19 2024-04-30 得克萨斯州大学系统董事会 靶向fanci、rad51和pbk抗原的肽和经改造t细胞受体及使用方法
CN115607573B (zh) * 2022-12-16 2023-05-23 北京大学第三医院（北京大学第三临床医学院） 一种用于调节杀伤性t细胞活性的方法、药物及其应用
IL325822A (en) * 2023-07-13 2026-03-01 Ltz Therapeutics Inc Multispecific antibodies and their uses
CN118834328B (zh) * 2024-07-02 2025-09-16 江苏海洋大学 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用
CN120183512B (zh) * 2025-05-23 2025-08-12 浙江省肿瘤医院 基于转录组测序构建的用于诊断早期宫颈癌淋巴结转移的方法、模型
CN120908452B (zh) * 2025-09-28 2025-12-02 吉林大学 一种用于卵巢癌初步筛查的试剂盒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342108B2 (en) * 1998-06-25 2008-03-11 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
WO2015018805A1 (en) * 2013-08-05 2015-02-12 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2766395A (en) * 1995-06-05 1996-12-24 Human Genome Sciences, Inc. Human g-protein receptor hgber32
EP1064022A4 (en) * 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PROTEINS AND THEIR USE
JP4315301B2 (ja) 1998-10-30 2009-08-19 独立行政法人科学技術振興機構 ヒトＨ３７タンパク質と、このタンパク質をコードする ｃＤＮＡ
US6680197B2 (en) * 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
GB0119473D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Compounds
EP1425393A4 (en) * 2001-08-21 2005-08-17 Millennium Pharm Inc SEARCH FOR CDC7 INHIBITORS
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
EP1622934A2 (en) * 2003-05-05 2006-02-08 Pharmacia Italia S.p.A. Truncated forms of human dbf4, complexes with their interacting partners and methods for identification of inhibitors thereof
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
JP4721903B2 (ja) * 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
US8536313B2 (en) * 2007-07-10 2013-09-17 Shionogi & Co., Ltd. Monoclonal antibody having neutralizing activity against MMP13
BRPI0813621A2 (pt) * 2007-07-27 2017-05-09 Immatics Biotechnologies Gmbh imunoterapia contra tumores neuronais e cerebrais
PL2565204T3 (pl) 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
EP2220245B1 (en) * 2007-10-17 2015-04-22 The Board of Trustees of The Leland Stanford Junior University Method and composition for crystallizing g protein-coupled receptors
WO2009123568A1 (en) 2008-03-31 2009-10-08 Agency For Science, Technology & Research High efficiency linear transmitter
TW201000115A (en) * 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
ITBO20090075A1 (it) * 2009-02-13 2010-08-14 Magneti Marelli Spa Macchina elettrica con singolo statore e due rotori tra loro indipendenti e veicolo stradale provvisto di tale macchina elettrica
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012048291A2 (en) * 2010-10-08 2012-04-12 Proteapex Therapeutics Llc Compositions and methods for inhibition of mmp:mmp-substrate interactions
WO2012104344A1 (en) * 2011-02-01 2012-08-09 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
HK1200037A1 (en) 2011-09-12 2015-07-31 克里蒂科斯有限责任公司 Non-invasive methods of detecting target molecules
EP2788012A4 (en) 2011-11-11 2015-08-05 Cedars Sinai Medical Center COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES
US9254311B2 (en) * 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EP3639831A1 (en) 2012-08-15 2020-04-22 Université de Montréal Method for identifying novel minor histocompatibility antigens
IL286786B (en) * 2012-09-14 2022-09-01 The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst T cell receptors that recognize mhc mage–a3 are restricted type ii
WO2014160275A2 (en) 2013-03-14 2014-10-02 Battell Memorial Institute Biomarkers for liver fibrosis
WO2015092710A1 (en) * 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3446119A1 (en) * 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342108B2 (en) * 1998-06-25 2008-03-11 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
WO2015018805A1 (en) * 2013-08-05 2015-02-12 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Also Published As

Publication number Publication date
AU2016313684B2 (en) 2020-04-02
TWI782290B (zh) 2022-11-01
TW202024115A (zh) 2020-07-01
US10898558B2 (en) 2021-01-26
SG10201807588TA (en) 2018-10-30
KR20180038550A (ko) 2018-04-16
TWI699377B (zh) 2020-07-21
AU2020201896A1 (en) 2020-04-02
US20200397879A1 (en) 2020-12-24
TW202041233A (zh) 2020-11-16
US10525114B2 (en) 2020-01-07
MA43459A1 (fr) 2019-08-30
CR20180174A (es) 2018-06-06
MA43461B1 (fr) 2021-03-31
TW202024113A (zh) 2020-07-01
US20180250374A1 (en) 2018-09-06
TWI722653B (zh) 2021-03-21
TWI722658B (zh) 2021-03-21
MX2018002480A (es) 2018-08-24
GB201515321D0 (en) 2015-10-14
JP7506026B2 (ja) 2024-06-25
US20200323968A1 (en) 2020-10-15
CR20200493A (es) 2020-11-24
JP2018532382A (ja) 2018-11-08
AU2016313684A1 (en) 2018-04-12
MA43461A1 (fr) 2019-08-30
TW202024111A (zh) 2020-07-01
TWI722660B (zh) 2021-03-21
AU2018250464A1 (en) 2018-11-15
EA201890560A1 (ru) 2018-08-31
AU2020201896B2 (en) 2022-08-25
JP2021118721A (ja) 2021-08-12
US10576132B2 (en) 2020-03-03
BR112018003460A2 (pt) 2018-09-25
UA124577C2 (uk) 2021-10-13
TWI722657B (zh) 2021-03-21
US11065316B2 (en) 2021-07-20
EA201891874A2 (ru) 2019-01-31
TW202024114A (zh) 2020-07-01
KR20180093123A (ko) 2018-08-20
TW202024127A (zh) 2020-07-01
TWI722655B (zh) 2021-03-21
TW201708246A (zh) 2017-03-01
TWI722654B (zh) 2021-03-21
CR20200492A (es) 2020-11-24
US20180250373A1 (en) 2018-09-06
MA43460A1 (fr) 2019-08-30
US10695411B2 (en) 2020-06-30
CR20200494A (es) 2020-11-24
CR20200495A (es) 2020-11-24
TW202024126A (zh) 2020-07-01
SG10202001830PA (en) 2020-04-29
TW202024112A (zh) 2020-07-01
MA43457A1 (fr) 2019-08-30
EA201891874A3 (ru) 2019-05-31
EP3461494A1 (en) 2019-04-03
CN107921111B (zh) 2022-07-26
TWI722664B (zh) 2021-03-21
US20200054729A1 (en) 2020-02-20
MA43458A1 (fr) 2019-08-30
KR102308798B1 (ko) 2021-10-05
PE20181517A1 (es) 2018-09-21
CA3072922A1 (en) 2017-03-09
TW201920233A (zh) 2019-06-01
TWI722663B (zh) 2021-03-21
SG10202001831SA (en) 2020-04-29
CR20180423A (es) 2018-11-19
CA2996963A1 (en) 2017-03-09
TWI722659B (zh) 2021-03-21
US10898557B2 (en) 2021-01-26
TWI722656B (zh) 2021-03-21
MA45073A (fr) 2019-04-03
CN107921111A (zh) 2018-04-17
TW202023608A (zh) 2020-07-01
KR102515909B1 (ko) 2023-03-29
US10568950B1 (en) 2020-02-25
KR20210122894A (ko) 2021-10-12
PE20181164A1 (es) 2018-07-19
TW202021613A (zh) 2020-06-16
AU2018250464B2 (en) 2020-04-09
WO2017036936A1 (en) 2017-03-09
US20200289631A1 (en) 2020-09-17
TW202023607A (zh) 2020-07-01
EP3341014A1 (en) 2018-07-04
US20200061170A1 (en) 2020-02-27
TW202024110A (zh) 2020-07-01
JP6970974B2 (ja) 2021-11-24
TWI722662B (zh) 2021-03-21
TW202024109A (zh) 2020-07-01
MA42694A (fr) 2018-07-04

Similar Documents

Publication Publication Date Title
JP7506026B2 (ja) 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ
US20220249632A1 (en) Peptides and t cells for use in immunotherapeutic treatment of various cancers
US20170056486A1 (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees